Abstract

BackgroundEpratuzumab is a humanized anti-CD22 monoclonal antibody in development for the treatment of moderate-to-severe systemic lupus erythematosus (SLE). Its efficacy in SLE has been demonstrated in three double-blind, placebo-controlled studies:...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call